IDHC vs. DXRX, AGL, YGEN, ABDX, PRM, GDR, VRCI, GENI, DMTR, and LLAI
Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), and LungLife AI (LLAI). These companies are all part of the "diagnostics & research" industry.
Integrated Diagnostics vs.
Diaceutics (LON:DXRX) and Integrated Diagnostics (LON:IDHC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
Integrated Diagnostics has a net margin of 17.21% compared to Diaceutics' net margin of -10.90%. Integrated Diagnostics' return on equity of 30.45% beat Diaceutics' return on equity.
Diaceutics currently has a consensus target price of GBX 160, indicating a potential upside of 11.19%. Given Diaceutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Diaceutics is more favorable than Integrated Diagnostics.
52.4% of Diaceutics shares are held by institutional investors. Comparatively, 43.0% of Integrated Diagnostics shares are held by institutional investors. 34.3% of Diaceutics shares are held by insiders. Comparatively, 34.0% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Diaceutics had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 2 mentions for Diaceutics and 1 mentions for Integrated Diagnostics. Integrated Diagnostics' average media sentiment score of 0.59 beat Diaceutics' score of 0.34 indicating that Integrated Diagnostics is being referred to more favorably in the news media.
Integrated Diagnostics has higher revenue and earnings than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.
Diaceutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Integrated Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Integrated Diagnostics received 41 more outperform votes than Diaceutics when rated by MarketBeat users. However, 88.24% of users gave Diaceutics an outperform vote while only 65.12% of users gave Integrated Diagnostics an outperform vote.
Summary
Integrated Diagnostics beats Diaceutics on 10 of the 18 factors compared between the two stocks.
Get Integrated Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Integrated Diagnostics Competitors List
Related Companies and Tools
This page (LON:IDHC) was last updated on 2/22/2025 by MarketBeat.com Staff